**EXPLANATORY STATEMENT**

*National Health Act 1953*

*National Health* *(Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (No. 2)*

PB 100 of 2020

**Authority**

This legislative instrument is made pursuant to subsections 85(7) and 100(2) of the *National Health Act 1953* (the Act).

Subsection 85(7) of the Act gives the Minister the power to determine the circumstances in which a prescription may be written for the supply of a pharmaceutical benefit.

Subsection 100(1) of the Act provides that the Minister may make special arrangements for, or in relation to, providing that an adequate supply of pharmaceutical benefits will be available to persons:

1. who are living in isolated areas: or
2. who are receiving treatment in circumstance which pharmaceutical benefits are inadequate for that treatment; or
3. if the pharmaceutical benefits covered by the arrangements can be more conveniently or efficiently supplied under the arrangements.

Subsection 100(2) of the Act provides that the Minister may vary or revoke a special arrangement made under subsection 100(1).

Subsection 33(3) of the *Acts Interpretation Act 1901* provides that where an Act confers a power to make, grant or issue any instrument of a legislative or administrative character (including rules, regulations or by-laws), the power shall be construed as including a power exercisable in the like manner and subject to the like conditions (if any) to repeal, rescind, revoke, amend, or vary any such instrument.

**Purpose**

The *National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (No. 2)* (the amendment instrument) amends the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* (PB 71 of 2012), and the *National Health (Highly specialised drugs program) Special Arrangement 2010* (PB 116 of 2010).

The amendment instrument changes the date of repeal of some of the provisions contained in PB 71 of 2012, and PB 116 of 2010 from 1 October 2020 to 1 April 2021. The amendment instrument ensures the temporary measures remain in effect during the current health pandemic.

**Background**

The *National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020* (PB 32 of 2020) temporarily modified the circumstances mentioned in Part 1 of Schedule 4 of PB 71 of 2012, and Schedule 3 of PB 116 of 2010 for circumstances codes for pharmaceutical benefits where:

* the patient has previously been supplied that pharmaceutical benefit; and
* having regard to the individual patient’s situation and the state of affairs associated with precautions against the spread of the coronavirus known as COVID-19, it is not reasonably practicable to establish those circumstances.

PB 32 of 2020 also determined that where the above criteria are met, the prescriber is required to keep a written record of the reason it is not practicable to establish the relevant circumstance.

The amendments in PB 32 of 2020 were intended to operate where patients may not be able to meet the continuing treatment circumstances for practical reasons in the context of the current COVID-19 pandemic, but it may be clinically inappropriate to cease their treatment. Some examples of situations that may result in patients being unable to meet continuing treatment circumstances include where a patient cannot attend an outpatient clinic to perform a test because the patient is required to quarantine or where a prescriber considers it would be appropriate for an immunocompromised patient to self‑isolate. Some examples of pharmaceutical benefits with circumstances that may not be able to be met are:

* The prescription of lumacaftor with ivacaftor for the treatment of cystic fibrosis for a patient who has previously received this treatment, where the patient is unable to attend a hospital outpatient clinic to have a lung function test due to COVID-19.
* The prescription of riociguat for the treatment of chronic thromboembolic pulmonary hypertension for a patient who has previously received this treatment, where the patient is unable to complete tests to demonstrate the benefit from therapy in an outpatient clinic due to COVID-19.
* The prescription of donepezil for the treatment of Alzheimer’s disease for a patient who has previously received this treatment, where the prescriber is unable to have the patient complete a mini mental state exam during a telehealth consultation and the patient is unable to attend a consultation in person due to COVID-19.
* The prescription of somatropin for slow growth for a patient who has previously received this treatment, where the patient is unable to have height, weight and bone age measurements to demonstrate the benefit from therapy due to COVID-19.

The provisions were due to be repealed at the start of 1 October 2020 but will now be repealed on 1 April 2021.

**Consultation**

This instrument affects authorised prescribers and patients who may be entitled to receive pharmaceutical benefits.

The Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body established by section 100A of the Act, made recommendations to the Minister for Health about which pharmaceutical benefits are subject to circumstances where, having regard to the patient’s situation and the state of affairs associated with precautions against the spread of the coronavirus known as COVID-19, it may not be reasonably practicable to establish those circumstances.

The PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. In addition, an industry nominee has been appointed to the PBAC. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.

The recommendations provided by the PBAC were informed by correspondence received from patient groups and pharmaceutical companies regarding subsidised access to growth hormone treatment and severe asthma treatment. The PBAC recommendations were also informed by enquiries from a number of prescribers concerning treatments for Alzheimer’s disease, cystic fibrosis, chronic thromboembolic pulmonary hypertension, Pulmonary Arterial Hypertension, rheumatoid arthritis, psoriatic arthritis and relapsed or refractory Stage III or IV CD20 positive follicular B-cell non‑Hodgkin's lymphoma.

The PBAC recommended that the provisions should continue to be in place until 31 March 2020, to allow patient access in situations where patients may not be able to meet the continuing treatment circumstances for practical reasons in the context of the current COVID-19 pandemic, but it may be clinically inappropriate to cease their treatment. The PBAC also advised upadacitinib for the treatment of rheumatoid arthritis, which listed on the PBS on 1 May 2020, should be included.

It was considered that further consultation for this instrument was unnecessary due to the nature of the consultation that had already taken place for PB 32 of 2020.

Details of the instrument are set out in the **Attachment**.

This instrument commences the day after it is registered.

This instrument is a legislative instrument for the purposes of the *Legislation Act 2003*.

**ATTACHMENT**

**Details of the *National Health (Pharmaceutical benefits) Legislation Amendment (Continuing treatment during Coronavirus pandemic) Instrument 2020 (No. 2)***

**1 Name**

This section provides that the name of this instrument is the *National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020) (No. 2)*. The instrument may also be cited as PB 100 of 2020.

**2 Commencement**

This section provides that the instrument commences the day after it is registered.

**3 Authority**

This section states that this instrument is made under subsections 85(7) and 100(2) of the *National Health Act 1953*.

**4 Schedules**

Section 4 provides that each instrument that is specified in a Schedule to the instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule has effect according to its terms.

**Schedule 1–Amendments**

Part 1 - Amendments of main listing instrument

*National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)*

**1 Subsection 10A(3)**

This section repeals the current date of repeal from subsection 10A(3) of PB 71 of 2012, being 1 October 2020. The date is replaced with a new repeal date of 1 April 2021.

**2 Schedule 6**

This section omits the table in schedule 6 and substitutes with a table that includes upadacitinib, tablet 15 mg, oral which was PBS listed on 1 May 2020.

Part 2 - Amendments of special arrangement

*National Health (Highly specialised drugs program) Special Arrangement (PB 116 of 2010)*

**3 Subsection 9AA(3)**

This section repeals the current date of repeal from subsection 9AA(3) of PB 116 of 2010, being 1 October 2020. The date is replaced with a new repeal date of 1 April 2021.

**Statement of Compatibility with Human Rights**

*Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011*

***National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (No. 2)***

**(PB 100 of 2020)**

This Disallowable Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011.*

**Overview of the Disallowable Legislative Instrument**

The *National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (No 2)* (the amendment instrument) amends the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* (PB 71 of 2012) and the *National Health (Highly specialised drugs program) Special Arrangement 2010* (PB 116 of 2010). The amendment instrument changes the repeal date of provisions contained in PB 71 of 2012, and PB 116 of 2010 from 1 October 2020 to 1 April 2021.

The *National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (PB 32 of 2020)* temporarily modified the circumstances mentioned in Part 1 of Schedule 4 of PB 71 of 2012, and Schedule 3 of PB 116 of 2010 for circumstances codes for pharmaceutical benefits where:

• a patient has previously been supplied that pharmaceutical benefit; and

• having regard to the patient’s situation and the state of affairs associated with precautions against the spread of the coronavirus known as COVID-19, it is not reasonably practicable to establish those circumstances.

The amendments in PB 32 of 2020 also determine that where the above criteria are met, the prescriber is required to keep a written record of the reason it is not practicable to establish the circumstance. The amendment instrument ensures the measures continue during the current health pandemic.

**Human rights implications**

This Disallowable Legislative Instrument engages Articles 2 and 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR) by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

The Pharmaceutical Benefits Scheme (PBS) is a benefit scheme which assists with advancement of this human right by providing for subsidised access by patients to medicines. The recommendatory role of the Pharmaceutical Benefits Advisory Committee ensures that decisions about subsidised access to medicines on the PBS are evidence-based.

**Conclusion**

This Disallowable legislative instrument is compatible with human rights because it advances the protection of human rights.